Around half of people diagnosed with pancreatic cancer will have been diagnosed with diabetes recently, according to NHS ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

Roche's Hemlibra treatment for haemophilia A is one of its top-selling drugs, making almost $5 billion last year, and the ...

A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic ...

EY's latest Biotech Beyond Borders report acknowledges the seismic changes in the US in the last few months, including cuts ...

Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...

The PMS requirement applies to all UKCA- and CE-marked devices, like in vitro diagnostics (IVDs), glucose monitors, and ...

Small transactions may not always make the headlines, but they’re the lifeblood of pharma innovation. So says Juergen ...

Understanding that communication and transparency from experts are critical enablers for widespread confidence in AI is the ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...